Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Pharmaceuticals

Claudia Stöllberger¹ 

[1] Krankenanstalt Rudolfstiftung, Second Medical Department, Juchgasse 25, Wien A-1030, Austria

关键词: atrial fibrillation;    dabigatran;    anticoagulation;   

DOI  :  10.3390/ph5020155

来源: mdpi

【 摘 要 】

Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.